For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
CJC-1295 is a synthetic GHRH analogue developed by ConjuChem Biotechnologies in two forms: CJC-1295 with DAC (half-life 6-8 days, weekly dosing, albumin-binding) and CJC-1295 without DAC / Modified GRF 1-29 (half-life approximately 30 minutes, pulsatile GH release). The primary human evidence is the Teichman 2006 Phase 1 RCT (JCEM) confirming 2-10 fold GH increases and 1.5-3 fold IGF-1 increases sustained for up to 28 days in healthy adults. The pharmaceutical development program was terminated after a Phase 2 death in 2006. It is the most widely used GH secretagogue in research protocols, typically combined with ipamorelin.
CJC-1295 requires two critical structural clarifications before reviewing its evidence base.
First, there are two chemically distinct compounds sold under variations of the name: CJC-1295 with DAC (Drug Affinity Complex) is the original ConjuChem compound, which includes a maleimidopropionyl-lysine modification enabling covalent binding to serum albumin Cys34, producing a 6-8 day half-life and once-weekly dosing. CJC-1295 without DAC (also called Modified GRF 1-29, Mod GRF 1-29, or tetrasubstituted GRF 1-29) retains the four DPP-4 resistant amino acid substitutions but lacks the DAC chemistry, producing a half-life of approximately 30 minutes similar to sermorelin. These are mechanistically different compounds with different pharmacokinetic profiles. The Teichman 2006 JCEM human data used CJC-1295 with DAC. Most current research protocols use CJC-1295 without DAC because pulsatile GH release more closely mirrors physiological rhythms and may reduce desensitization risk.
Second, the pharmaceutical development history must be front-loaded: a Phase 2 trial in 192 HIV-positive patients with lipodystrophy (NCT00267527) was halted in July 2006 after one participant died of myocardial infarction approximately 3 hours after their 11th dose. The attending physician attributed the death to underlying asymptomatic coronary artery disease with plaque rupture unrelated to treatment. Development was discontinued as a precaution nonetheless. Causality was never established -- but the pharmaceutical development program that generated the only human efficacy data beyond Phase 1 was permanently terminated. This history is essential context for evaluating any clinical application claims.
The regulatory status in the US is actively contested: the FDA placed CJC-1295 on its Category 2 compounding prohibition list in 2023, then removed it in September 2024 when nominators withdrew their submissions -- not because safety concerns were resolved. The FDA Pharmacy Compounding Advisory Committee meeting of December 4, 2024 reviewed the compound. Its current compounding status is legally unresolved as of March 2026.
CJC-1295 was developed by ConjuChem Biotechnologies (Montreal, Canada) as part of their Drug Affinity Complex (DAC) bioconjugation platform, which enables covalent binding of therapeutic peptides to endogenous albumin to extend plasma half-life. The base peptide is a 29-amino acid GHRH fragment (GHRH 1-29) identical in length to sermorelin, with four strategic amino acid substitutions that confer resistance to enzymatic degradation:
Position 2: Alanine replaced with D-alanine -- flips chirality to prevent DPP-4 cleavage at the critical N-terminal site. Position 8: Asparagine replaced with glutamine -- prevents deamidation. Position 15: Glycine replaced with alanine -- stabilizes the backbone. Position 27: Methionine replaced with leucine -- prevents oxidation.
These four modifications convert the 10-minute half-life of native GHRH(1-29) (sermorelin) into a compound stable enough to survive in circulation. The DAC modification -- a maleimidopropionyl-lysine at position 30 -- then adds the albumin-binding chemistry that extends the half-life to 6-8 days.
CJC-1295 without DAC (Modified GRF 1-29) retains the four stability substitutions but lacks the albumin-binding chemistry. Its half-life of approximately 30 minutes closely mimics sermorelin and endogenous GHRH, producing discrete GH pulses. The research community predominantly uses this form in combination with ipamorelin, because pulsatile GH release preserves physiological feedback mechanisms and avoids the continuous "GH bleed" associated with the DAC version that may promote receptor desensitization.
The therapeutic rationale for CJC-1295 development was to provide a long-acting GHRH analogue for treatment of HIV-associated lipodystrophy and adult GH deficiency -- the same target indication that tesamorelin ultimately achieved FDA approval for in 2010. ConjuChem's program was a direct competitor to Theratechnologies' tesamorelin program until its termination in 2006.
CJC-1295 (both forms) acts as a GHRH receptor (GHRHR) agonist on anterior pituitary somatotrophs, activating the Gs protein -- adenylyl cyclase -- cAMP -- PKA signaling cascade to stimulate GH synthesis and release. This is the same receptor and signaling pathway as sermorelin and tesamorelin.
The four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) do not alter the receptor binding domain or affinity -- they exclusively address metabolic stability. The GHRHR interaction is preserved and equivalent to native GHRH. The DAC modification (covalent albumin binding at position 30) further extends plasma residence time without affecting receptor pharmacology.
The somatostatin negative feedback mechanism: GH secretion is regulated by the interplay between GHRH (stimulatory) and somatostatin (inhibitory). CJC-1295, like all GHRH analogs, remains subject to somatostatin feedback, which provides a physiological ceiling on GH elevation. This is the primary safety feature distinguishing GHRH analogs from exogenous rhGH -- the somatostatin brake prevents supraphysiological GH exposure. The Ionescu 2006 JCEM study confirmed that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation, with intact somatostatin-mediated pulsatility maintained even under sustained GHRH receptor activation.
Synergy with GH secretagogues (ipamorelin, GHRP-6): CJC-1295 activates GHRHR; ipamorelin activates GHS-R1a (ghrelin receptor). These are two entirely distinct receptor systems converging on GH release. Simultaneous activation of both pathways produces synergistic GH secretion substantially greater than either compound alone -- the mechanistic basis of the widely used CJC-1295/ipamorelin combination protocol. This synergy exploits the same two-receptor architecture tesamorelin lacks (tesamorelin is GHRH-only, with no GHS-R1a component).
IGF-1 production: sustained GH elevation from CJC-1295 drives hepatic IGF-1 synthesis, which then mediates downstream anabolic, lipolytic, and tissue-repair effects. The Teichman 2006 data demonstrated IGF-1 elevations of 35-120% above baseline lasting 9-11 days after a single CJC-1295 with DAC injection.
Teichman 2006 (Phase 1, CJC-1295 with DAC): After a single injection, dose-dependent increases in mean plasma GH concentrations of 2-10 fold for 6 days or more, and mean plasma IGF-1 concentrations of 1.5-3 fold for 9-11 days. Estimated half-life: 5.8-8.1 days. After multiple doses, mean IGF-1 levels remained above baseline for up to 28 days. Evidence of cumulative effect after multiple doses. No serious adverse reactions reported. Well-tolerated at 30 and 60 mcg/kg.
Ionescu 2006 (pulsatility study): CJC-1295 administration increased trough and mean GH secretion and IGF-1 production with preserved GH pulsatility. Trough GH levels increased 7.8-fold, which was the dominant driver of IGF-1 elevation. GH pulse amplitude and frequency were maintained, confirming that continuous GHRH receptor stimulation does not eliminate pulsatile GH release under the restraint of intact somatostatin feedback.
The Teichman 2006 Phase 1 study is the most methodologically rigorous human evidence for CJC-1295 and the foundation of the entire human evidence base. It confirms that the mechanism works in humans: GH and IGF-1 are elevated in a dose-dependent, prolonged fashion. The Ionescu 2006 pulsatility confirmation is mechanistically important -- it demonstrates that physiological feedback (somatostatin ceiling) is preserved, distinguishing this from supraphysiological GH axis stimulation. However, these are pharmacokinetic/pharmacodynamic studies demonstrating mechanism, not clinical efficacy studies demonstrating therapeutic benefit for any specific indication. GH and IGF-1 elevation are endpoints, not outcomes.
The trial enrolled 192 participants across sites in North and South America and had just completed enrollment at the time of termination. No efficacy results from this trial were ever published -- it was halted before efficacy data collection was complete.
The termination event: One participant at an Argentinian site died approximately 3 hours after receiving their 11th CJC-1295 injection, with chest discomfort and confirmed cardiac arrest via ECG. The cause of death was determined to be myocardial infarction. The attending physician's assessment was that the most likely explanation was underlying asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to CJC-1295 treatment. Development was discontinued as a precaution.
Context: This was the same indication (HIV lipodystrophy) for which tesamorelin was being developed simultaneously by competitor Theratechnologies. Tesamorelin continued development and received FDA approval in 2010. ConjuChem's CJC-1295 program, which would have offered once-weekly vs. tesamorelin's once-daily dosing, never had its visceral fat reduction data published.
The terminated Phase 2 is the defining clinical fact about CJC-1295: the only trial designed to demonstrate clinical efficacy was halted before producing efficacy data. The lipodystrophy indication was mechanistically sound and represented a legitimate unmet need -- the same need tesamorelin successfully addressed. Whether CJC-1295 would have matched tesamorelin's 15-20% visceral fat reduction is unknowable. The death, while attributed to pre-existing disease by the attending physician, ended the program. This is not merely an absence of evidence -- the trial that would have provided evidence was terminated.
There are zero published prospective human trials examining CJC-1295's effects on body composition -- lean mass, fat mass, visceral fat, waist circumference, or metabolic parameters -- in any population. All body composition claims for CJC-1295 in research and compounding practice are extrapolations from: (1) GH/IGF-1 biology; (2) tesamorelin body composition data from the same receptor mechanism; (3) anecdotal clinical observation from compounding-era practitioners.
The mechanistic premise is sound: GHRH receptor activation drives GH secretion, which drives hepatic IGF-1 production. GH promotes lipolysis particularly in visceral adipose tissue (highest GH receptor density) and has anabolic effects on skeletal muscle. These effects are dose-dependent and well-established in GH biology.
The evidence gap is the same as ipamorelin's: the mechanism is credible, the target biology is established, but no human trial has tested whether CJC-1295's GH/IGF-1 elevation translates to clinically meaningful body composition changes in any population.
Zero human body composition data specific to CJC-1295 or Modified GRF 1-29. The mechanistic pathway to body composition effects is coherent and supported by the established GH biology and by tesamorelin's Phase 3 body composition data. But mechanism is not evidence of effect, and the magnitude of GH elevation achievable with CJC-1295 (without the daily dosing that gave tesamorelin its consistent visceral fat reduction) is unknown in terms of body composition outcome. This is the largest evidentiary gap between widespread clinical use and published data in this compound's profile.
GHRH itself (independent of pituitary GH release) has direct sleep-promoting effects via hypothalamic GHRH receptors on sleep-regulatory neurons. CJC-1295, acting as a GHRH receptor agonist, would be expected to share these sleep-promoting effects through the same hypothalamic pathway.
There are no published controlled human sleep studies with CJC-1295 specifically. The sleep quality improvement reported in compounding-era clinical experience is consistent with the established GHRH-SWS biology but is not independently validated with objective sleep endpoints for this compound.
Clinical observation in research settings consistently notes improved sleep quality with GH secretagogue use, particularly in patients with age-related GH decline, but this evidence comes from practitioner reports and observational data rather than controlled trials.
Sleep quality improvement is the most mechanistically grounded off-label application after body composition, because the GHRH-SWS connection is independently established in basic sleep science (not just derived from IGF-1/GH biology). However, no CJC-1295-specific sleep endpoint study has been published. This application is plausible extrapolation from established GHRH sleep science rather than validated clinical benefit for this specific compound.
The CJC-1295 without DAC + ipamorelin combination is the most widely used GH secretagogue protocol in research and compounding practice, based on a mechanistically compelling rationale that has never been tested in a controlled human trial.
The synergy mechanism is established: GHRHR activation (CJC-1295) and GHS-R1a activation (ipamorelin) use independent intracellular calcium-cAMP pathways that converge on somatotroph GH release. Co-stimulation consistently produces greater GH release than either pathway alone in animal models -- the published Bowers data typically shows 2-3 fold amplification of GH response compared to either compound alone.
The combination is preferred over CJC-1295 with DAC + ipamorelin because Modified GRF 1-29's 30-minute half-life produces discrete GH pulses temporally aligned with ipamorelin's acute GH release rather than continuous baseline elevation.
No human body composition, clinical efficacy, or outcomes data exists for the combination. The protocol is based entirely on: (1) individual compound mechanism confirmation in humans; (2) synergy demonstrated in animal models; (3) compounding-era practitioner observation.
The CJC-1295 without DAC + ipamorelin combination is the most commercially significant research protocol associated with CJC-1295, yet has the weakest evidentiary foundation of any named compound combination reviewed in this research series. The mechanistic rationale is sound. The GH synergy in animal models is real. But no human RCT has ever tested this combination for any clinical endpoint -- not body composition, not sleep quality, not metabolic parameters, not anti-aging outcomes. The combination's widespread use in compounding practice substantially outpaces its human evidence base.
DAC form dosed weekly; no-DAC form dosed daily. Often stacked with Ipamorelin.
CJC-1295 is not FDA-approved and not legally available as a compounded prescription product in a clearly defined manner as of March 2026. The compound's compounding status has been contested since 2023. For genuine research use: CJC-1295 without DAC (Modified GRF 1-29) and CJC-1295 with DAC are available as research-grade peptides from specialty chemical suppliers. HPLC purity 98% or above required; mass spec confirmation of the 29-AA sequence with correct modifications; endotoxin below 1 EU/mg for injectable use. The D-Ala2 modification and DAC chemistry require specialized analytical methods for purity verification -- a legitimate manufacturing concern cited by the FDA.
CJC-1295 vs. tesamorelin (direct structural competitor): Both are GHRH analogues targeting the same receptor for the same originally intended indication (HIV lipodystrophy). Tesamorelin received FDA approval in 2010. CJC-1295's development was terminated in 2006 after a Phase 2 death. Tesamorelin has Phase 3 RCT data from 806 patients; CJC-1295 has Phase 1 data from approximately 100 subjects. The pharmacokinetic comparison actually favors CJC-1295 with DAC (once-weekly vs. tesamorelin's once-daily), but this advantage never reached clinical validation.
CJC-1295 vs. sermorelin (evidence comparison): Sermorelin has former FDA approval (1990 diagnostic; 1997 pediatric GHD therapeutic), documented adult aging body composition data, and the Vitiello/Merriam cognitive function program. CJC-1295 has a longer half-life but less human clinical data than the compound it pharmacokinetically improves upon. By human evidence standards, sermorelin is better characterized despite CJC-1295's pharmacokinetic advantages.
CJC-1295 vs. ipamorelin (comparison of the two combination partners): Both are unapproved, both had their primary development indications fail, and both have only Phase 1 mechanism-confirmation data. Ipamorelin's sole completed human efficacy trial failed its primary endpoint (POI trial, P=0.15). CJC-1295's sole Phase 2 trial was halted before efficacy data was collected. Together they form a combination protocol used by hundreds of thousands of people, built on mechanism confirmation studies and animal model synergy, without a single human RCT of the combination itself.
CJC-1295's safety profile derives from Phase 1 trial data in healthy adults (Teichman 2006, approximately 100 subjects across dose groups) and limited compounding-era clinical observation. No post-marketing safety database exists because the compound was never approved.
Phase 1 (Teichman 2006): No serious adverse reactions reported across ascending single-dose and multiple-dose trials at 30, 60, 90, and 125 mcg/kg. Adverse events were mild and transient -- injection site reactions, transient flushing, headache, and mild gastrointestinal symptoms at higher doses.
Phase 2 death (2006): One participant in the lipodystrophy Phase 2 (NCT00267527) died of myocardial infarction approximately 3 hours after their 11th weekly injection. The attending physician attributed this to underlying asymptomatic coronary artery disease with plaque rupture -- unrelated to treatment. Development was discontinued as a precaution, not because causality was established. This event must be documented but should not be interpreted as confirmed drug-related mortality.
FDA-documented safety concerns for CJC-1295: Cardiovascular effects -- dose-dependent increases in heart rate and systemic vasodilation (flushing, warmth, transient hypotension) documented in Phase 1 data. Immunogenicity -- compounded peptide preparations can generate immune responses including antibody formation and rare anaphylaxis; one anaphylaxis case reported in approximately 500 patients in available data (0.2% rate). Unnatural amino acids (D-Ala) complicate manufacturing characterization and purity assessment. Long-term safety is entirely unstudied -- no trial has assessed CJC-1295 beyond 7 weeks.
Class concerns shared with all GH-axis compounds: IGF-1 elevation and theoretical cancer promotion risk; glucose counter-regulation (GH is insulin-antagonistic); no carcinogenicity studies conducted. These are theoretical class risks, not compound-specific findings for CJC-1295.
CJC-1295 is in an unusual evidence position: the most widely used GH secretagogue compound in research practice, yet one of the worst-validated in terms of human clinical efficacy data. The Teichman 2006 Phase 1 trial confirmed that the mechanism works in humans -- GH and IGF-1 are elevated substantially and durably by CJC-1295 administration. What was never established is whether this GH/IGF-1 elevation produces any of the clinical outcomes that drive its use: body composition improvements, anti-aging effects, sleep quality enhancement, or any disease-specific benefit.
The termination of the Phase 2 lipodystrophy trial is not a minor gap in the evidence base. It is the evidence base. The trial that would have provided clinical efficacy data was permanently halted. The compound that succeeded in the same indication with the same mechanism (tesamorelin) has Phase 3 body composition data from 806 patients. CJC-1295 has none.
The practical comparison to sermorelin is instructive: sermorelin has former FDA approval, documented adult aging body composition data from the Khorram 1997 study (small but controlled), and a well-characterized safety profile from decades of approved clinical use. CJC-1295 has a cleaner pharmacokinetic advantage (longer half-life than sermorelin) but less clinical evidence than the compound it pharmacokinetically improves upon.
For the research community using the CJC-1295 without DAC + ipamorelin combination: the mechanistic rationale is sound, the GH synergy is real, and the individual compound mechanisms are confirmed in separate human trials. What does not exist is a single human RCT demonstrating that this combination produces the body composition, performance, or wellness outcomes that motivate its use. This is a meaningful evidence gap, not a research detail.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use